Glycogen disorder disease


Published on

Published in: Health & Medicine
  • Be the first to comment

No Downloads
Total Views
On Slideshare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Glycogen disorder disease

  2. 2. INTRODUCTIONThese are group of inherited inborn errors of metabolism due to deficiency or dysfunction of enzymes related to glycogen metabolism.Usually manifestations are confined to liver and muscle but some cause more generalized pathology and affect tissues such as the kidney, heart and bowel.
  3. 3. GLYCOGENGlycogen is the storage polysaccharide and is sometimes called animal starch.It is highly branched structure with chains of 12–14 α-D-glucopyranose residues.Most of the glucose residues in glycogen are linked by α-1-4-glycosidic bonds.Branches at about every 4th to 10th residue are created by α-1,6-glycosidic bonds.The chains are arranged in concentric layers.
  8. 8. GLYCOGEN STORAGE DISORDERS (GSD)• Glycogen storage disease is a generic term to describe group of inherited disorders characterized by deposition of an abnormal type or quantity of glycogen in tissues, or failure to mobilize glycogen.• GSD were categorized numerically in the order in which enzymatic defects were identified.• They are also classified by the organs involved & clinical manifestations.• Overall incidence is estimated at 1 / 20,000 live births.• Inheritance patterns - Autosomal recessive (I, II, III, IV, V, VII, some IX). - X-linked (some IX, VI)
  9. 9. LIVER GLYCOGEN STORAGE DISEASEIa / Von Gierke Glucose-6-phosphatase Common, Severe hypoglycemia, hepatic adenomas & ca, renal failureIb Glucose-6-phosphate ~10% of type I translocaseIIIa / cori or forbes Liver & muscle debranching Common, mild hypoglycemia, hepatic enzyme adenoma & carcinomaIIIb Liver debranching enzyme ~15% of type IIIVI /Hers Liver phosphorylase Rare , often benignIX Liver phosphorylase kinase Common, x-linked,0 Glycogen synthase Decreased glycogen storeXI / Fanconi-Bickel Glucose transporter-2 Rare ,consanguinity in 70%DISORDER WITH LIVER CIRRHOSISIV / Andersen Branching enzyme One of rarer glycogenoses
  10. 10. MUSCLE GLYCOGEN STORAGE DISEASEV / McArdle Muscle phosphorylase Common, male predominanceVII / Tarui phosphofructokinase Ashkenazijews & japanesePhosphoglycerate kinase deficiency Rare , x-linkedPhosphoglycerate mutase deficiency Rare , african , americanLactate dehydrogenase Lactic acid Rare dehydrogenaseFructose 1,6-bisphosphate aldose A deficiency RarePyruvate kinase deficiency muscle isozyme RareMuscle phosphorylase kinase deficiency Rare , autosomal recessiveB-enolase deficiency Muscle b-enolase rare
  11. 11. GLYCOGEN STORAGE DISEASE CAUSING SKELETALMYOPATHY AND / OR CARDIOMYOPATHYII / Pompe Lysosomal acid Common, undetectable, or a-glucosidase very low level of enzyme activity on infantile formCardiac phosphorylase kinase deficiency Severe cardiomyopathy & early heart failure, Very rare
  12. 12. TYPE I, VON GIERKES DISEASE Itis the most common GSDAffected enzyme: glucose-6-phosphataseAffected tissue: Liver, kidney and intestinal mucosaTwo subtypes-1. Type I a- glucose-6-phosphatase enzyme is defective2. Type I b- glucose-6-phosphatase translocase is defective
  13. 13.  Clinical features: Neonatal period - Hypoglycemia & lactic acidosisHepatomegaly by 3-4 months of ageEasy bruising & epistaxis d/t prolonged bleedingtime.Kidneys - enlarged, but normal spleen & heart sizeHyperuricemia and hyperlipidemia.Type I b - neutropenia with reccurrent infection, oral & mucosal ulceration.
  14. 14. Long term complications Puberty delayed Gout becomes symptomatic by puberty. Increased bleeding during menstrual cycles- life threatening menorrhagia 2nd & 3rd decade - hepatic adenoma > haemorrhage > malignant. Renal - proteinuria, Hypertension, stones, altered creatinine, complete failure.
  15. 15. TYPE II, POMPES DISEASE Affected enzyme- α-1,4-glucosidase (acid maltase)Clinical feature: Clinical spectrum is continuous &broad, with presentation in infants, children and adults.1. Infantile Form Infant normal at birth, develop generalised muscle weakness with feeding difficulties, Hepatomegaly, cardiomegaly, CHF due to HCMP death before 1 yr of age2. Juvenile form Delayed motor milestones & difficulty in walking Swallowing difficulties , proximal Ms weakness & respiratory Ms involvement & death before end of 2nd
  16. 16. 3. Adult form Slowly progressive myopathy without overt cardiac involvement. Onset between 2nd & 7th decade Dominated by progressive muscle weakness with truncal involvement. Pelvic girdle, paraspinal Ms & diaphragm are seriously affected.
  17. 17. TYPE III, CORI OR FORBES DISEASEAffected enzyme: Glycogen debranching enzymeAffected tissues: Liver and muscleSubtypes: 1. type III a - Both liver & muscle involved 2. type III b – Only liver involved (15%)Clinical features: Hepatomegaly, hypoglycemia, short stature, variable skeletal myopathy and cardiomyopathy. Hyperlipidemia, elevated liver transaminases. Hepatomegaly improves with age. Liver cirrhosis & hepatocellular carcinoma may occur in late adulthood.
  18. 18. TYPE IV, ANDERSENS DISEASE, AMYLOPECTINOSISAffected enzyme: Glycogen branching enzymeAffected tissues: LiverClinical features: – Hepatomegaly, failure to thrive, cirrhosis, splenomegaly, jaundice, hypotonia, waddling gait, lumbar lordosis.Treatment: Liver transplant.Prognosis: Mostly death within 4 yr of age due to cirrhosis and portal hypertension.
  19. 19. TYPE V, MCARDLES DISEASE Affected enzyme: Muscle phosphorylase deficiency Affected tissue: Muscle Clinical features Symptoms develop in adulthood with exercise intolerance & muscle cramps Two types of activity – 1 .Brief exercise of great intensity 2. Less intensity but sustained activity 35% report permanent pain that seriously affects sleep & other activities. Half of pt report burgundry-coloured urine after exercise, resulting from myoglobinuria 20 to rhabdomyolysis, which later can lead to renal failure.
  20. 20. TYPE VI, HERS DISEASE Affected enzyme: Liver phosphorylase Affected tissues: Liver, rare cardiac form Clinical features: Most common variant is X-linked Hepatomegaly, hypoglycemia, growth retardation, hyperlipidemia.Treatment: Cardiac transplantation for rare cardiac formPrognosis: Usually normal life span.
  21. 21. TYPE VII, TARUI DISEASE Affected enzyme: Phosphofructokinase(PFK)Affected tissue: MuscleClinical features:Exercise intolerance, muscle cramping, exertional myopathy, compensated haemolysis & myoglobinuria.Note : Symptoms can be similar to McArdlesGlycogen Storage Disease but more severe.
  22. 22. TYPE IX, GLYCOGEN STORAGE DISEASE Affected enzyme: liver phosphorylase kinase deficiency Different subtypes – Gene/subunit involved, Tissue affected, Mode of inheritance Clinical features Child 1-5 yr age – growth retardation, hepatomegaly Cholesterol, triglycerides & liver enzymes mildly elevated. Fasting ketosis, mild hypoglycemia. Most adult reach normal final Ht & practically asymptomatic Prognosis is good, hepatomegaly & abnormal blood chemistries return to normal with age.
  23. 23. TYPE 0, LEWIS DISEASEAffected enzyme: Hepatic glycogen synthase.Affected tissues: Liver.Clinical features Seizures can occur. Fatigue and muscle cramps after exertion. Mild growth retardation in some cases.
  24. 24. INVESTIGATION Blood tests: – Blood glucose: hypoglycemia is likely – Liver function tests: monitoring for hepatic failure – Anion gap calculation: may indicate lactic acidaemia – Urate – Creatinine clearance Urine tests: Myoglobinuria after exercise found in 50% of people with McArdles disease.
  25. 25. INVESTIGATION ImagingUSG abdomen - hepatomegalyEchocardiography - to look for cardiac involvement in certain types of GSD BiopsyOf liver.Muscle or other tissues gives definitive diagnosis.
  26. 26. DIAGNOSIS Clinical presentation Abnormal biochemical parameters Liver & muscle biopsy for enzyme deficient. Gene based mutation analysis.prenatal diagnosis: chorionic villus sampling andamniocentesis can be used to determine enzyme activity in a fetus.
  27. 27. TREATMENT Supportive treatment maintaining normal blood sugar level Supplementation of multivitamins, calcium & vit DAllopurinol - raised uric acid. ACE-inhibitors - microalbuminuria. Statin - hyperlipidemia Diet therapy : high-protein, low-carbohydrate diet Physiotherapy and occupational therapy may be required
  28. 28. TREATMENT Enzyme replacement therapy – Pompe disease Alglucosidase alfa (Myozyme) recombinant human acid alpha - glucosidase at 20 mg/kg every 2 weeks Genetic counsellingGene therapy remains a potentially effective treatment for the future.